Login / Signup

Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.

Maria PolyzoiMattias EkmanAnja ReithmeierJohanna JacobEmma KarlssonEvelina BertranouBarbro LinderholmRobert Hettle
Published in: PharmacoEconomics - open (2023)
At list price, adjuvant olaparib is a cost-effective alternative to WaW in patients with gBRCA1/2-mutated, high-risk, HER2-negative eBC in Sweden.
Keyphrases
  • early breast cancer
  • early stage
  • wild type
  • combination therapy